Detalles de la búsqueda
1.
Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Cancer Immunol Immunother
; 71(11): 2597-2608, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35304622
Resultados
1 -
1
de 1
1
Próxima >
>>